A systems approach to cancer therapy

Cancer and Metastasis Reviews

Volumn 15, Issue 2, 1996, Pages 247-272

  Teicher, Beverly A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Antiangiogenic agents; Combined modality therapy; Lewis lung carcinoma; Minocycline; TNP 470

Indexed keywords

CYCLOPHOSPHAMIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; MINOCYCLINE;

CANCER THERAPY; EXTRACELLULAR MATRIX; LEWIS CARCINOMA; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0030018743     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00437479     Document Type: Review

References (316)

1. Paget S: The distribution of secondary growths in cancer of the breast. Lancet (March 23): 571-573, 1989
2. Poste G, Paruch L: Stephen Paget, M.D., F.R.C.S., (1855-1926): A Retrospective. Cancer Metastasis Rev 8: 93-97, 1989
3. Mareel MM, Van Roy FM, Bracke ME: How and when do tumor cells metastasizt? Critical Reviews in Oncogenesis (4)5: 559-594, 1993
4. Kohn EC: Development and prevention of metastasis. Anticancer Res 13: 2553-2560, 1993
5. Freitas I, Baronzio GF: Neglected factors in cancer treatment: cellular interactions and dynamic microenvironment in solid tumors. Anticancer Res 14: 1097-1102, 1994
6. Wellstein A: Growth factor targeted and conventional therapy of breast cancer. Breast Ca Res Trtmt 31: 141-152, 1994
7. Connolly JL, Ducatman BS, Schnitt SJ, Dvorak AM, Dvorak HF: Principles of cancer pathology. In: Holland JF, Frei III E, Bast Jr. RC, Kufe DW, Morton DL, Weichselbaum RR (eds) Caneer Medicine. Lea & Febiger, Philadelphia, PA, 1993, pp 432-450
8. Cotran RS, Kumar V, Robbins SL: Neoplasia (4th ed.), W.B. Saunders Co., Philadelphia, PA, 1989, p 239-305
9. Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New Eng J Med 315: 1650-1659, 1986
10. Nagy JA, Brown LF, Senger DR, Lanir N, Van De Water L, Dvorak AM, Dvorak HF: Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 948: 305-326, 1989
11. Hodde C, Miodonski A, Bakker C, Veltman WAM: Scanning electron microscopy of microcorrosion casts with special attention on arterio-venous differences and application to the rat's cochlea. Scan Electron Microsc (II): 477-484, 1977
12. Burger PC, Chandler DB, Klintworth GK: Scanning electron microscopy of vascular casts. J Elec Micro Tech 1: 341-348, 1984
13. Hammersen F, Endrick B, Messmer K: The fine structure of tumor blood vessels. Int J Microcirc: Clin Exp 4: 31-43, 1985
14. Fahrenbach WH, Bacon DR, Morrison JC, Van Buskirk EM: Controlled vascular corrosion casting of the rabbit eye. J Elec Micro Tech 10: 15-26, 1988
15. Schraufnagel DE, Schmid A: Microvascular casting of the lung: effects of various fixation protocols. J Elec Micro Tech 8: 185-191, 1988
16. Falk P: Differences in vascular pattern between the spontaneous and the transplanted C3H mouse mammary carcinoma. Eur J Cancer 18: 155-165, 1982
17. Warren BA: The vascular morphology of tumors. In: Peterson HI (ed) Tumor blood circulation. CRC Press, Boca Raton, FL, 1979. pp 1-47
18. Falk P: Patterns of vasculature in two pairs of related fibrosarcomas in the rat and their relation to tumour response to single large doses of radiation. Eur J Cancer 14: 237-250, 1978
19. Jain RK: Determinants of tumor blood flow: a review. Cancer Res 48: 2641-2658, 1988
20. Peters W, Teixeira M, Intaglietta M, Gross JF: Microcirculatory studies in rat mammary carcinoma. I. Transparent chamber method, development of microvasculature and pressures in tumor vessels. J Natl Cancer Inst 65: 631-642, 1980
21. Zweifach BW: I. Analysis of pressure distribution in the terminal vascular bed in cat mesentery. Circ Res 34: 843-857, 1974
22. House SD, Johnson PC: Diameter and blood How of skeletal muscle venules during local flow regulation. Am J Physiol 250: H828-H837, 1986
23. Schmid-Schoenbein GW, Zweifach BW, Kovalcheck S: The application of stereological principles to morphometry of the microcirculation in different tissues. Microvasc Res 14: 303-317, 1977
24. Dewhirst MW, Tso CY, Oliver R, Gustafson CS, Secomb TW, Gross JF: Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. Int J Radiat Oncol Biol Phys 17: 91-99, 1989
25. Endrich B, Intaglietta M, Reinhold HS, Gross JF: Hemodynamic characteristics in microcirculatory blood channels during early tumor growth. Cancer Res 39: 17-23, 1979
26. Endrich B, Hammersen F, Gotz, A, Messmer K: Microcirculatory blood flow, capillary morphology, and local oxygen pressure of the hamster amelanotic melanoma A-Mel-3. J Natl Cancer Inst 68: 475-485, 1982
27. Less JR, Skalak TC, Sevick EM, Jain RK: Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 51: 265-273, 1991
28. Skalak TC, Schmid-Schönbein GW: The microvasculature in skeletal muscle. IV. A model of the capillary network. Microvasc Res 32: 333-347, 1986
29. Vaupel P: Oxygen supply to malignant tumors. In: Peterson H-I (ed) Tumor blood circulation: angiogenesis, vascular morphology, and blood flow of experimental and human tumors. CRC Press Inc., Boca Raton, FL. 1979. pp 143-168
30. Awwad HK, El Naggar ME, Mocktar N, Barsoum M: Intercapillary distance measurement as an indicator of hypoxia in carcinoma of the cervix uteri. Int J Radiat Oncol Biol Phys 12: 1329-1333, 1986
31. Tannock IF, Steel GG: Quantitative techniques for study of the anatomy and function of small blood vessels in tumors. J Natl Cancer Inst 42: 771-782, 1969
32. Lauk S, Zietman A, Skates S, Fabian R, Suit HD: Comparative morphometric study of tumor vasculature in human squamous cell carcinomas and their xenotransplants in athymic nude mice. Cancer Res 49: 4557-4561, 1989
33. Folkman J: Tumor angiogenesis: therapeutic implications. New Eng J Med 285: 1182-1186, 1971
34. Folkman J: Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175: 409-416, 1972
35. Voyta JC, Via DP, Butterfield CE, Zetter BR: Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J Cell Biol 99: 2034-2040, 1984
36. Folkman J, Klagshrun M: Angiogenic factors. Science 235: 442-447, 1987
37. Folkman J: What is the role of angiogenesis in metastasis from cutaneous melanoma? Eur J Cancer Clin Oncol 23: 361-363, 1987
38. Folkman J, Watson K, Ingher D, Hanahan D: Induction of angiogenesis during the transition from hyperplasis to neoplasia. Nature 339: 58-61, 1989
39. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990
40. Haimovitz-Friedman A, Vlodavsky I, Chaudhuri A, Witte L, Fuks Z: Autocrine effects of fihroblast growth factor in repair of radiation damage in endothelial cells. Cancer Res 51: 2552-2558, 1991
41. Folkman J, Shing Y: Angiogenesis. J Biol Chem (267)16: 10931-10934, 1992
42. Shing Y, Folkman J, Haudenschild C, Lund D, Crum R, Klagshrun M: Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor. J Cell Biochem 29: 275-287, 1985
43. Thomas KA: Fibroblast growth factors. FASEB J 1: 434-440, 1987
44. Rifkin DB, Moscatelli D: Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol (109)1: 1-6, 1989
45. Burgess WH, Maciag T: The heparin-binding (fibroblast) growth factor family of proteins. Ann Rev Biochem 58: 575-606, 1986
46. Gospodarowicz D: Fibroblast growth factor and its involvement in developmental processes. Curr Top Dev Biol 24: 57-93, 1990
47. Klagsbrun M, D'Amore PA: Regulators of angiogenesis. Annu Rev Physiol 53: 217-239, 1991
48. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L: Basic fibroblast growth factor induces angiogenesis in vitro. Proceedings of the National Academy of Sciences U.S.A. (83)19: 7297-7301, 1986
49. Thomas KA, Rios-Candelore M, Gimenz-Gallego G, DiSalvo J, Bennett C, Rodkey J, Fitzpatrick S: Pure brain-derived acidic fibroblast growth factor is a potent angiogenic vascular endothelial cell mitogen with sequence homology to interleukin 1. Proceedings of the National Academy of Sciences U.S.A. 82: 6409-6413, 1985
50. Lobb RR, Alderman EM, Fett JW: Induction of angiogenesis by bovine brain derived class 1 heparin-binding growth factor. Biochemistry (24)19: 4969-4973, 1985
51. Baird A, Ling A: Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: implications for a role of heparinase-like enzymes in the neovascular response. Biochem Biophys Res Commun 142: 428-435, 1987
52. Shing Y: Heparin-copper hiaffinity chromatography of fibroblast growth factors. J Biol Chem (263)18: 9059-9062, 1988
53. Moscatelli D, Presta M, Rifkin DB: Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration. Proceedings of the National Academy of Sciences U.S.A. 83(7): 2091-2095, 1986
54. Presta M, Moscatelli D, Joseph-Silverstein J, Rifkin DB: Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production. DNA synthesis, and migration. Mol Cell Biol (6)1: 4060-4066, 1986
55. Slack JM, Darlington BG, Heath JK, Godsave SF: Mesoderm induction in early Xenopus embryos by heparin-binding growth factors. Nature 326: 197-200, 1987
56. Kimmelman D, Kirschner M: Synergistic induction of mesoderm by FGF and TGF-beta and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell (51)5: 869-877, 1987
57. Vlodavsky J, Folkman J, Sullivan R, Fridman R, Ishai-Michaeli R, Sasse J, Klagsbrun M: Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proceedings of the National Academy of Sciences U.S.A. (84)8: 2292-2296, 1987
58. Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun (161)2: 851-858, 1989
59. Gospodarowicz D, Abraham JA, Schilling J: Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proceedings of the National Academy of Sciences U.S.A. (86)19: 7311-7315, 1989
60. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J: Tumor vascular permeability factor stimulates endothelial growth and angiogenesis. Journal of Clinical Investigators (84)5: 1470-1478, 1989
61. Pepper MS, Ferrara N, Orci L, Montesano R: Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun (181)2: 902-906, 1991
62. Leung ZW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (246)4935: 1306-1309, 1989
63. Plouet J, Schilling J, Gospodarowicz D: Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J (8)12: 3801, 1989
64. Conn G, Soderman DD, Schaeffer MT, Wile M, Hatcher VB, Thomas KA: Purification of a glycoprotein vascular endothelial cell milogen from a rat glioma-derived cell line. Proceedings of the National Academy of Sciences U.S.A. (87)4:1323-1327.1990
65. Myoken Y, Kayada Y, Okamoto T, Kan M, Sato GH, Sato JD: Vascular cndothelial cell growth factor (VEOF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites. Proceedings of the National Academy of Sciences U.S.A. (88)13: 5819-5823, 1991
66. Rosenthal RA, Megyesi J, Henzel WJ, Ferrara N, Folkman J: Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor. Growth Factors (4)1:53-59, 1990
67. Connolly DT, Ulander JV, Heuvelman D, Nelson R, Monsell R, Siegel N, Haymore BL, Leimgruber R, Feder J: Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 264: 20017-20024, 1989
68. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (246)4935: 1309-1312, 1989
69. Conn G, Bayne ML, Soderman DD, Kwok PW, Sullivan KA, Palisi TM, Hope DA, Thomas KA: Amino acid and cDNA sequences of a vascular endothelial cell milogen that is homologous to platelet-derived growth factor. Proceedings of the National Academy of Sciences U.S.A. (87)7: 2628-2632, 1990
70. Tischer E, Mitchell R, HartmanT, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem (266) 18:11947-11954, 1991
71. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL: Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 55: 510-513, 1995
72. Samoto K, Ikezaki K, Ono M, ShonoT, Kohno K, Kuwano M, Fukui M: Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55: 1189-1193, 1995
73. Shweiki D, Neeman M, Itin A, Keshet E: Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implication for tumor angiogenesis. Proc Nat Acad Sci 92: 768-772, 1995
74. Plate KH, Breier D, Weich HA, Mennel HD, Risau W: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59: 520-529, 1994
75. 121) produced by Saccharomyces cerevisiae promotes both angiogenesis and vascular permeability. Biochim Biophys Acta 1243: 195-202, 1995
76. Luger TA, Schwarz T: Evidence for an epidermal cytokine network. J Invest Dermatol 95: 100S-104S, 1990
77. Oliveira IC, Sciavolino PJ, Lee TH, Vilcek J: Downregulation of interleukin-8 gene expression in human fibroblssts: unique mechanism of transcriptional inhibition by interferon. Proceedings of the National Academy of Sciences U.S.A. 89: 9049-9053, 1992
78. Baggiolini M, dark-Lewis I: Interleukin-8, a chemotactic and inflammatory cytokine. Federation of European Biochemical Societies 307: 97-101, 1992
79. Bickel M: The role of interleukin-8 in inflammation and mechanisms of regulation. J Perio Res 64: 456-460, 1993
80. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Einer VM, Einer SG, Stricter RM: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258: 1798-1801, 1992
81. Aman MJ, Rudolf G, Goldschmitt J, Aulitzky WE, Lam C, Huber C, Peschel C: Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. Blood 82: 2371-2378, 1993
82. Ishikawa F, Miyazone K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W, Heldin C-H: Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature (338)6216: 557-562, 1989
83. Fell JW, Strydom DJ, Lob RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL: Isolation and characterization of angiogenin, and angiogenic protein from human carcinoma cells. Biochemistry (24)20: 5480-5486, 1985
84. Bicknell R, Vallee BL: Angiogenin activates endothelial cell phospholipase. Proceedings of the National Academy of Sciences U.S.A. (85)16: 5961-5965, 1988
85. Bicknell R, Vallee BL: Angiogenin stimulates endothelial cell prostacyclin secretion by activation of phospholipase. Proceedings of the National Academy of Sciences U.S.A. (86)5: 1573-1577, 1989
86. Shapiro R, Riordan JF, Vallee BL: Characteristic rihonucleolytic activity of human angiogenin. Biochemistry (25) 12: 3527-3532, 1986
87. St. Clair DK, Ryback SM, Riordan JF, Vallee BL: Angiogenin abolishes cell free protein synthesis by specific peptide inactivation of ribosomes. Proceedings of the National Academy of Sciences U.S.A. 84: 8330-8334, 1987
88. Hu G-F, Riordan JF, Vallee BL: Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc Nat Acad Sci USA 91: 12096-12100, 1994
89. Olson KA, Felt JW, French TC, Key ME, Vallee BL: Angiogenin antagonists prevent tumor growth in vivo. Proc Nat Acad Sci USA 92: 442-446, 1995
90. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N: Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature (329) 6140: 630-632, 1987
91. Frater-Schroder M, Risau W, Hallman R, Gautschi P, Bohlen P: Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proceedings of the National Academy of Sciences U.S.A. (84)15: 5277-5281, 1987
92. Okamura K, Sato Y, Matsuda T, Hamanaka R, Ono M, Kohno K, Kuwano M: Endogenous basic fibroblast growth factor-dependent induction of collagenase and interleukin-6 in tumor necrosis factor-treated human microvascular endolhelial cells. J Biol Chem (266)29: 19162-19165, 1991
93. Beutler B, Cerami A: Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature (320) 6063: 584-588, 1986
94. Schreiber AB, Winkler ME, Derynck R: Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth facience (232)4755:1250-1253, 1986
95. Derynck R: Transforming growth factor-alpha. Mol Reprod Dev (27)1: 3-9, 1990
96. Roberts AB, Sporn MB, Assoian RK, Smith JM, Rocher NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS: Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proceedings of the National Academy of Sciences U.S.A. (83)12: 4167-4171, 1986
97. Sporn MB, Roberts AB: Peptide growth factors. SpringerVerlag, Berlin, 1990, p 419-472
98. Dobson DE, Kambe A, Block E, Dion T, Lu H, Castellot Jr. JJ, Spiefelman BM: 1-Butyryl-glycerol: a novel angiogenesis factor secreted by differentiating adipocytes. Cell (61)2: 223-230, 1990
99. Form DM, Auerbach R: PGE2 and angiogenesis. Proc Soc Exp Biol Med (172)2: 214-218, 1983
100. Ziehe M, Jones J, Gullino P: The role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst (69)2: 475-482, 1982
101. BenEzra D: Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants. Am J Opthal (86)4: 455-461, 1978
102. Graeber JE, Glaser BM, Setty BNY, Jerdan JA, Walega RW, Stuart MJ: 15-Hydroxyeicosatetraenoic acid stimulates migration of human retinal microvessel endothelium in vitro and neovascularization in vivo. Prostaglandin (39)6: 665-673, 1990
103. Kull Jr. FC, Brent DA, Parikh I, Cuatrecasas P: Chemical identification of a tumor-derived angiogenic factor. Science (236)4803: 843-845, 1987
104. Fraser RA, Ellis M, Stalker AL: Experimental angiogenesis in the chorioallantoic membrane. In: Lewis DH (ed) Current advances in basic and clinical Microcirculatory Research. S. Karger AG, Basel, 1979, pp 25-27
105. Dusseau JW, Hutchins PM, Malbasa DA: Stimulation of angiogenesis by adenosine on the chick chorioallantoic membrane. Circ Res (59)2: 163-170, 1986
106. West DC, Hampson IN, Arnold F, Kumar S: Angiogenesis induced by degradation products of hyaluronic acid. Science (228)4705: 1324-1326, 1985
107. Masferrer JL, Rimarachin JA, Gerrifsen ME, Falck JR, Yadagiri P, Dunn MW, Laniado SM: 12(R)-hydroxyeicosatrienoic acid, a potent chemotactic and angiogenic factor produced by the cornea. Exp Eye Res (52)4: 417-424, 1991
108. Laniado-Schwartzman M, Lavrovsky Y, Stoltz RA, Conners MS, Falck JR, Chauhan K, Abraham NG: Activation of nuclear factor KB and oncogene expression by 12(R)-hydroxyeicosatrienoic acid, an angiogenic factor in microvessel endothelial cells. J Biol Chem (269)39: 24321-25327, 1994
109. Oikawa T, Suganuma M, Ashino-Fuse H, Shimamura M: Okadaic acid is a potent angiogenesis inducer. Jpn J Cancer Res (83)1: 6-9, 1992
110. Mustonen T, Alitalo K: Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol (129)4: 895-898, 1995
111. van der Geer P, Hunter T, Lindberg RA: Receptor proteintyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10: 251-337, 1994
112. Blood CH, Zetter BR: Tumor interactions with the vasculature: angiogenesis and tumor metastases. Biochim Biophys Acta 1032: 89-118, 1990
113. Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, BarShavit R, Fuks Z: Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 9: 203-226, 1990
114. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991
115. Zetter BR: Cell motility in angiogenesis and tumor metastasis. Cancer Invest (8)6: 669-671, 1990
116. Dorudi S, Hart IR: Mechanisms underlying invasion and metastasis. Curr Opin One 5: 130-135, 1993
117. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (Lond) 284: 67-68, 1980
118. Liotta LA, Thorgeirrson UP, Garbisa S: Role of collagenases in tumor cell invasion. Cancer Metastasis Rev (1)4: 277-288, 1982
119. Liotta LA, Stetler-Stevenson W: Metalloproteinases and malignant conversion: does correlation imply causality? J Natl Cancer Inst (81)8: 556-557, 1989
120. Sanchez-Lopez R, Nicholson R, Gesnel MC, Matrisan LM, Mreathnach R: Structure-function relationships in the collagenase family member transin. J Biol Chem (263)24: 11892-11899, 1988
121. Muller D, Quantin B, Gesnel MC, Abecassis J, Breathnach R: The collagenase gene family in humans consists of at least four members. Biochem J (253)1: 187-192, 1988
122. Chin JR, Murphy G, Werb Z: Stromelysin, a connective tissue-degrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase. Biosynthesis, isolation, characterization, and substrates. J Biol Chem (260)22: 12367-12376, 1985
123. Wilhelm SM, Collier IE, Kronberger A, Eisen Z, Marmer BL, Grant GA, Bauer EA, Goldberg GI: Human skin fibroblast stromelysin: structure, glycosylation, substrate specificity, and differential expression in normal and tumorigenic cells. Proceedings of the National Academy of Sciences U.S.A. (84)19: 6725-6729, 1987
124. Ostrowski LE, Finch J, Krieg P, Matrisian L, Patskan G, O'Connell JF, Phillips J, Slaga TG, Breathnach R, Bowden GT: Expression pattern of a gene for a secreted metalloproteinase during late stages of tumor progression. Mol Carcinog (1)1: 13-19, 1988
125. Paganetti PA, Caroni P, Schwab ME: Glioblastoma infiltration into central nervous system tissue in vitro: involvement of a metalloprotease. J Cell Biol (107)6 Pt 1: 2281-2291, 1988
126. Chen JM, Chen WT: Fibronectin-degrading proteases from the membranes of transformed cells. Cell (48)2: 193-203, 1987
127. Werb Z, Tremble PM, Behrendtsen O, Crowley E, Damsky CH: Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. J Cell Biol 109: 877-889, 1989
128. Thorgeirsson UP, Turpeenniemi-Hujanen T, Williams JE, Westin EH, Heilman CA, Talmadge JE, Liotta LA: NIH/3T3 cells transfected with human tumor DNA containing activated ras oncogenes express the metastatic phenotype in nude mice. Mol Cell Biol 5: 259-262, 1985
129. Garbisa S, Pozatti R, Mushchcl RJ, Safiotti U, Ballin M, Goldfarb RH, Khoury G, Liotta LA: Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-E1a. Cancer Res (47)6: 1523-1528, 1987
130. Carlson SA, Ramshaw IA, Warrinton RC: Involvement of plasminogen activator production with tumor metastasis in a rat model. Cancer Res (44)7: 1122-1127, 1984
131. Eisenbach L, Sega S. Feldman M: Proteolytic enzymes in tumor metastases. II. Collagenase Type IV activity in subcellular tractions of cloned tumor cell populations. J Natl Cancer Inst 74: 87-93, 1985
132. Sullivan LM, Wuigley JP: An anticatalytic monoclonal antibody to avian plasminogen activator: its effect on behavior of RSV-transformed chick fibroblasts. Cell (45)6: 905-915, 1986
133. Ramshaw IA, Badenoch-Jones P, Grant A, Maxcted M, Claudianus C: Enhanced plasminogen activator production by highly metastatic variant cell lines of a rat mammary adenocarcinoma. Invasion Metastasis 6: 133-144, 1986
134. Ostrowski LE, Ashon A, Suthan BP, Pagast P, Bain DL, Wong C, Patel A, Schultz RM: Selective inhibition for proteolytic enzymes in an in vivo mouse model for experimental metastasis. Cancer Res 46: 4121-4128, 1986
135. Sappino AP, Busso N, Belin D, Vassali JD: Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res (47)15: 4043-4046, 1987
136. Evers JL, Patel J, Madcja JM, Schneider SL, Hobika GH, Camiola SM, Markus G: Plasminogen activator activity and composition in human breast cancer. Cancer Res (42)1: 219-226, 1982
137. Ossowoski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611-619, 1983
138. Ossowski L: Plasminogen activator dependent pathways in the dissemination of human tumor cells in chick embryo. Cell (52)3: 321-328, 1988
139. Hearing VJ, Law LW, Corti A, Appella E, Blasi F: Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 48: 1270-1278, 1988
140. Axelrod JH, Reich R, Miskin R: Expression activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Mol Cell Biol (9)5: 2133-2141, 1989
141. Sloane BF, Dunn JR, Honn KV: Lysosomal cathepsin B: correlation with metastatic potential. Science (212)4499: 1151-1152, 1981
142. Sloane BF, Honn KV, Sadler JG, Turner JJ, Taylor JD: Cathepsin B activity in B16 melanoma cells: a possible marker for metastatic potential. Cancer Res 42: 980-986, 1982
143. Koppel P, Baici A, Keist R, Matsu S, Keller R: Cathepsin B-like enzymes. Subcellular distribution and properties in neoplastic and control cells from human ectocervix. Exp Cell Biol (52)8: 293-299, 1984
144. Sloane BF, Rozchin J, Johnson K, Taylor H, Chrissman JD, Honn KV: Cathepsin B: association with plasma membrane in metastatic tumors. Proceedings of the National Academy of Sciences U.S.A. 83: 2483-2487, 1986
145. Rozhin J, Robinson D, Stevens MA, Lah TT, Honn KV, Ryan RE, Sloane BF: Mesoderm induction in early Xenopus embryos by heparin-binding growth factors. Cancer Res 40: 550-556, 1987
146. Kao TR, Stern R: Elastases in human breast carcinoma cell lines. Cancer Res (46)3: 1355-1358, 1986
147. Nemoto S, Koiso K, Aoyagi K, Takahashi S: Elastase - does this enzyme play any role in bladder cancer invasion? J Urol (134)5: 996-998, 1986
148. Zeydel M, Nakagawa S, Biempica L, Takahashi S: Collagenase and elastase production by mouse mammary adenocarcinoma primary cultures and cloned cells. Cancer Res (46)12 Pt 1: 6438-6445, 1986
149. Yusa T, Blood CH, Zetter BR: Tumor cell interactions with elastin: implications for pulmonary metastasis. Am Rev Respir Dis (140)5: 1458-1462, 1989
150. Kao RT, Wong M, Stern R: Elastin degradation by proteases from cultured human breast cancer cells. Biochem Biophys Res Commun (105)1: 383-389, 1982
151. Hornebeck W, Brechmeier D, Bollon G, Adnet JJ, Robert L: Proteinases and Tumor Invasion. Raven Press, New York, 1980, p 117-139
152. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher V: Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res (43)6: 2704-2711, 1983
153. Nakajima M, Irimura T, Di Ferrante D, Di Ferrante N, Nicolson GL: Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science (220)4597: 611-613, 1983
154. Corcoran ML, Steller-Stevenson WG, Brown PD, Wahl LM: Interleukin-4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes. J Biol Chem 267: 515-519, 1992
155. Henry N, van Lasmsweerde A-L, Vaes G: Collagen degradation by metastatic variants of Lewis Lung Carcinoma: cooperation between tumor cells and macrophages. Cancer Res 43: 5321-5327, 1983
156. Templeton NS, Stetler-Stevenson WG: Identification of a basal promoter for the human Mr 72,000 type IV collagenase gene and enhanced expression in a highly metastatic cell line. Cancer Res 51: 6190-6193, 1991
157. Pyke C, Ralfkiaer E, Huhtala P, Hurskainen T, Dano K, Tryggvason K: Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res 52:1336-1341, 1992
158. Overall CM, Wrana JL, Sodek J: Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/Type IV collagenase by transforming growth factor-β1 in human fibroblasts. J Biol Chem (266)21: 14064-14071, 1991
159. Coucke P, Baramova E, Leprince P, DePauw-Gillet M-C, Foidart J-M, Bassleer R: Metalloproteinases and serine proteases activities in mixed spheroids of mouse B16 melanoma cells and fibroblasts. Int J Oncol 5: 1125-1130, 1994
160. Roskelley CD, Desprez PY, Bissell MJ: Extracellular matrix-dependent tissue-specific gene expression in mammary epithelial cells requires both physical and biochemical signal transduction. Proc Nat Acad Sci USA 91: 12378-12382, 1994
161. r 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res 53: 5802-5807, 1993
162. r 92,000b Type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 53: 140-146, 1993
163. r 92,000 Type IV collagenase in human brain tumors. Cancer Res 53: 2208-2211, 1993
164. Alvarez OA, Carmichael DF, DeClerck YA: Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 82: 589-595, 1990
165. Terranova VP, Hujanen ES, Martin GR: Basement membrane and the invasive activity of metastatic tumor cells. J Natl Cancer Inst 77: 311-316, 1986
166. Tryggvason K, Hoyhtya M, Salo T: Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 907: 191-217, 1987
167. Taylor S, Folkman J: Protamine is an inhibitor of angiogenesis. Nature 297: 307-312, 1982
168. Groopman JE, Scadden DT: Interferon therapy for Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Int Med 110: 335-337, 1989
169. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL: Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. Med Intell 18: 1197-1200, 1989
170. Stricter RM, Kunkel SL, Arenberg DA, Burdick MD, Polverini PJ: Interferon γ-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun (210)1: 51-57, 1995
171. Kolber DL, Knisely TL, Maione TE: Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 87: 304-309, 1995
172. Stetler-Stevenson WG, Krutzsch HC, Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 264: 17374-17378, 1989
173. Welgus HG, Stricklin GP: Human skin fibroblast collagenase inhibitor. Comparative studies in human connective tissues, serum, and amniotic fluid. J Biol Chem 258: 12259-12264, 1983
174. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87: 581-586, 1995
175. Kerbel RS, Hawley RG: Interleukin 12: newest member of the antiangiogenesis club. J Natl Cancer Inst (87)8: 557-558, 1995
176. Banks RE, Patel PM, Selby PJ: Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer 71: 655-659, 1995
177. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994
178. Lee A, Langer R: Shark cartilage contains inhibitors of tumor angiogenesis. Science 221: 1185-1187, 1983
179. Moses MA, Sudhalter J, Langer R: Identification of an inhibitor of neovascularization from cartilage. Science 248: 1408-1410, 1990
180. Taylor CM, Weiss JB: Partial purification of a 5.7 K glycoprotein from bovine vitreous which inhibits both angiogenesis and collagenase activity. Biochem Biophys Res Commun 133: 911-916, 1985
181. DeClerck YA: Purification and characterization of a collagenase inhibitor produced by bovine vascular smooth muscle cells. Arch Biochem Biophys 265: 28-37, 1988
182. 2, Cancer Res 51: 903-906, 1991
183. Bogden AE, Taylor JE, Moreau J-P, Coy DH, LePage DJ: Response of human lung tumor xenografts to treatment with asomatostatin analogue (somatuline). Cancer Res 50: 4360-4365, 1990
184. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin
185. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164, 1994
186. Cheresh DA: Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Nat Acad Sci USA 84: 6471-6475, 1987
187. Folkman J, Weisz PB, Joullie MM, Li WW, Ewing WR: Control of angiogenesis with synthetic heparin substitutes. Science 243: 1490-1493, 1989
188. Crum R, Szabo S, Folkman J: A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230: 1375-1378, 1985
189. Folkman J, Langer R, Lingardt R, Haudenschild C, Taylor S: Angiogenesis inhibition and tumour regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221: 719-725, 1983
190. Lee K-E, Iwamura M, Cockett ATK: Cortisone inhibition of tumor angiogenesis measured by a quantitative colorimetric assay in mice. Cancer Chemother Pharmacol 26: 461-163, 1990
191. Ingber D, Folkman J: Inhibition of angiogenesis through modulation of collagen metabolism. Lab Inves 59: 44-51, 1988
192. Oikawa T, Hirotani K, Nakamura O, Shudo K, Hiragun A, Iwaguchi T: A highly potent antiangiogenic activity of retinoids. Cancer Lett 48: 157-162, 1989
193. Sharpe RJ, Kadin ME, Harmon DC, Imber MJ, Anderson RR: Complete resolution of Kaposi's sarcoma with systemic etretinate therapy in a patient with mycosis fungoides. J Am Acad Dermatol 20: 1123-1124, 1989
194. Schwartz JL, Flynn E, Shklar G: The effects of carotenoids on the antitumor immune response in vivo and in vitro with hamster and mouse immune effectors. In: Bendich A, Chandra RK (ed) Symposium on micronutrients and immune functions. New York Academy of Science, New York, 1990, pp 92-96
195. Schwartz JL, Flynn E, Trickler D, Shklar G: Directed lysis of experimental cancer by beta carotene in liposomes. Nutr Cancer 16: 107-112, 1991
196. Schwartz JL, Shklar G: A cyanobacteria extract and beta carotene stimulates an antitumor immune response against oral cancer cell line. Phytother Res 3: 243-248,1989
197. Schwartz JL, Singh R, Teicher B, Wright JE, Trites DH, Shklar G: Induction of a 70-kDa protein associated with the selective cytotoxicity of beta carotene in human epidermal carcinoma. Biochem Biophys 169: 941-946, 1990
198. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueño F, Paredes-Casillas P, Hong WK, Masimini G, Holdener EE, Krakoff IH: 13-cis-retinoic acid plus interferon-α2a in locally advanced squamous cell carcinoma of the cervix. J Natl Cancer Inst 85: 499-500, 1993
199. Schwartz JL, Suda D, Light G: Beta carotene is associated with the regression of hamster buccal pouch carcinoma and the induction of tumor necrosis factor in macrophages, Biochem Biophys Res Commun 136: 1130-1135, 1986
200. Shklar G, Schwartz JL: Tumor necrosis factor in experimental cancer regression with vitamin E, B-carotene, canthaxanthin and algae extract. Eur J Cancer 24: 839-850, 1988
201. Smith MA, Parkinson DR, Cheson BO, Friedman MA: Retinoids in cancer therapy. J Clin Oncol 10: 839-864, 1992
202. Chiocca E, Davies P, Stein J: The molecular basis of retinoic acid action. J Biol Chem 263: 11584-11589, 1988
203. Cowan J. Vanhoff D, Dinesman A: Use of a human tumor cloning system to screen retinoids for antineoplastic activity. Cancer 51: 92-96, 1983
204. Lotem J, Sachs L: Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation competent and defective myeloid leukemic cells. Cell Growth Differ 4: 41-47, 1993
205. Schwartz JL: β-carotene induced programmed cell death. J Dent Res 72: 285, 1993
206. Schwartz JL, Antoniades DZ, Zhao S: Molecular and biochemical reprogramming of oncogenesis through the activity of prooxidant or antioxidant. N Y Acad of Scie 686: 262-278, 1993
207. Alles A, Sulik K: Retinoic acid-induced limb-reduction defects: perturbations of zones of programmed death as a pathogenetic mechanism. Teratology 40: 163-171, 1989
208. Rohertson K, Mueller L, Collins S: Retinoic acid receptors in myeloid leukemia: characterization of receptors in retinoic acid resistant K-562 cells. Blood 77: 340-347, 1991
209. Tabin C: Retinoids, homeoboxes, and growth factors: toward molecular models for limb development. Cell 66: 199-217, 1991
210. Schwartz JL, Tanaka J, Khandekar V, Herman TS, Teicher BA: β-carotene and/or vitamin E as modulators of alkylating agents in SCC-25 human squamous carcinoma cells. Cancer Chemother Pharmacol 29: 207-213, 1992
211. Denekamp J: Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66: 181-196, 1993
212. Malone TE, Sharpe RJ: Development of angiogenesis inhibitors for clinical applications. Trends Biol Sci 11: 457-461, 1990
213. Teicher BA, Schwartz JL, Holden SA, Ara G, Northey D: In vivo modulation of several anticancer agents by β-carotene. Cancer Chemother Pharmacol (34)3: 235-241, 1994
214. Garewal H, List A, Meyskens F: Phase II trial of fenretinide (N-(4-hydroxyphenyl) retinamide in myelodysplasia. Possible retinoid, induced disease acceleration. Leuk Res 13: 339-343, 1989
215. Hong WK, Lippman SM, Itri LM: Prevention of secondary primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. New Eng J Med 323: 795-801, 1990
216. Schwartz JL, Antoniades DZ: β-carotene triggers enhanced expression of 70 kD stress protein and tumor suppresser p53 in association with the inhibition of oral carcinogenesis. Cancer Detect Prev (in press): 1995
217. Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W: Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D, and their combination. Cancer Lett 75: 35-39, 1993
218. Barnes S, Grubbs C, Setchell KDR, Carlson J: Soybeans inhibit mammary tumor in models of breast cancer. In: Pariza M, Liss AR (ed) Mutagens and carcinogens in the diet. Wiley-Liss, New York, 1990, pp 239-253
219. Akiyama T, Ishida J, Nakawaga S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem (262) 12: 5592-5595, 1987
220. Okura A, Arakawa H, Oka H, Yoshinari T, Monden Y: Effect of genistein on toposiomerase activity and on the growth of [Val12]Ha-ras-transformed NIH 3Y3 cells. Biochem Biophys Res Commun 157: 183-189, 1988
221. Zwiller J, Sassone-Corsi P, Kakazu K, Boyton AL: Inhibition of PDGF-induced c-jun and c-fos expression by a tyrosine protein kinase inhibitor. Oncogene 6: 219-221, 1991
222. Linassier C, Pierre M, Le Peco J-B, Pierre J: Mechanisms of action in NIH-3T3 cells of genistein, an inhibitor of EGF receptor tyrosine kinase activity. Biochem Pharmacol 39: 187-193, 1990
223. Yamashita Y, Kawada S, Nakano H: Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem Pharmacol 39: 737-744, 1990
224. Markovits J, Linassier C, Fosse P, Couprie J, Pierre J, Jacquemin-Sablon A, Saucier JM, Le Peca JB, Larsen AK: Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA toposiomerase II. Cancer Res (49)18: 5111-5117, 1989
225. Peterson G, Barnes S: Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun 179: 661-667, 1991
226. McCabe Jr. MJ, Orrenius S: Genistein induces apoptosis in immature human thymocytes by inhibiting toposiomerase-II. Biochem Biophys Res Commun (194)2: 944-950, 1993
227. Kanatani Y, Kasukabe T, Hozumi M, Motoyoshi K: Genistein exhibits preferential cytotoxicity to a leukemogenic variant but induces differentiation of a non-leukemogenic variant of the mouse monocytic leukemia Mm cell line. Leuk Res (17)10: 847-853, 1993
228. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, Schweigerer L: Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Nat Acad Sci USA 90: 2690-2694, 1993
229. Sjoberg ER, Chammas R, Ozawa H, Kawashima I, Khoo K-H, Morris HR, Dell A, Tai T, Varki A: Expression of deN-acetyl-gangliosides in human melanoma cells is induced by genistein or nocodazole. J Biol Chem (270)7: 2921-2930, 1995
230. Uckun FM, Evans WE, Forsyth CJ, Waddick KG, Ahlgren LT, Chelstrom LM, Burkhardt A, Bolen J, Myers DE: Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 267: 886-889, 1995
231. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557, 1990
232. Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D, Folkman J: Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 174: 1070-1076, 1991
233. Brem H, Ingber D, Blood CH, Bradley D, Urioste S, Folkman J: Suppression of tumor metastasis by angiogenesis inhibition. Surg Forum 42: 439-441, 1991
234. Brem H, Folkman J: Analysis of experimental antiangiogenic therapy. J Ped Surg 28: 445-451, 1993
235. Takayamiya Y, Friedlander RM, Brem H, Malick A, Martuza RL: Inhibition of angiogenesis and growth of human nerve sheath tumors by AGM-1470. J Neurosurg 78: 470-476, 1993
236. Brem H, Gresser I, Grossfeld J, Folkman J: The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Ped Surg 28: 445-451, 1993
237. Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K: Inhibitory effect of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. Cancer Res 53: 2566-2570, 1993
238. Kamei S, Okada H, Inoue Y, Yoshioka T, Ogawa Y, Toguchi H: Antitumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. J Pharmacol Exper Ther (264)1: 469-474, 1993
239. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T: Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(Chloroacetyl-carbamoyl)fumagillin (TNP-470; AGM-1470). Cancer Res 53: 4262-4267, 1993
240. Toi M, Tamamoto Y, Imazawa T, Takayanagi T, Akutsu K, Tominaga T: Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats. Int J Oncol 3: 525-528, 1993
241. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T: Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 53: 5233-5236, 1993
242. Schoof DD, Obando JA, Cusack Jr. GC, Goedegebuure PS, Brem H, Eherlein TJ: The influence of angiogenesis inhibitor AGM-1470 on immune system status and tumor growth in vitro. Int J Cancer 55: 630-635, 1993
243. Teicher BA, Holden SA, Ara G, Alvarez Sotomayor E, Huang ZD, Chen Y-N, Brem H: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int J Cancer 57: 920-925, 1994
244. Teicher BA, Dupuis N, Kusumoto T, Robinson MF, Liu F, Menon K, Coleman CN: Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Invest 2: 269-276, 1995
245. Teicher BA, Holden SA, Dupuis NP, Kakeji Y, Ikebe M, Emi Y, Goff D: Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Ca Res Trtmt 36: 227-236, 1995
246. Teicher BA, Dupuis NP, Robinson M, Emi Y, Goff D: Anti-angiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncology Res (7)5: 237-243, 1995
247. Teicher BA, Holden SA, Ara G, Dupuis N, Liu F, Yuan J, Ikebe M, Kakeji Y: Influence of an anti-angiogenic treatment on 9L gliosarcoma oxygenation and response to cytotoxic therapy. Int J Cancer (61)5: 732-737, 1995
248. Konno H, Tanaka T, Matsuda I, Kanai T, Maruo Y, Nishino N, Nakamura S, Baba S: Comparison of the inhibitory effect of the angiogenesis inhibitor. TNP-470. and mitomycin C on the growth and liver metastasis of human colon cancer. Int J Cancer 61: 268-271, 1995
249. Hori A, Ikeyama S, Sudo K: Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells. Biochem Biophys Res Commun (204)3: 1067-1073, 1994
250. Tanaka T, Konno H, Matsuda I, Nakamura S, Baba S: Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res 55: 836-839, 1995
251. Murata J, Saiki I, Makabe T, Tsuta Y, Tokura S, Azuma I: Inhibition of tumor-induced angiogenesis by sulfated chitin derivatives. Cancer Res 51: 22-26, 1991
252. Teicher BA, Alvarez Solomayor E, Huang ZD, Ara G, Holden S, Khandekar V, Chen Y-N: β-Cyclodextrin tetradecasulfate/tetrahydrocortisol ± minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma. Cancer Chemother Pharmacol 33: 229-238, 1993
253. Teicher BA, Holden SA, Ara G, Northey D: Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents. Anticancer Res 13: 2101-2106, 1993
254. Larsson EK, Joki A, Stälhandske T: Mechanism of action of the new immunomodulator LS26166 on T-cell responses. Int J Immunopharmacol 9: 425-431, 1987
255. Harning R, Koo GC, Szalay J: Regulation of the metastasis of murine ocular melanoma by natural killer cells. Invest Ophthalmol Visual Sci 30: 1909-1915, 1989
256. Kalland T: Effects of the immunomodulator LS-2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res 46: 3018-3022, 1986
257. Harning R, Szalay J: A treatment for metastasis of murine ocular melanoma. Invest Ophthalmol Visual Sci 29: 1505-1510, 1988
258. Tarkowski A, Gunnarsson K, Nilsson LA, Lindholm L, Stälhandske T: Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new autoimmunomodulator. Arthritis Rheum 29: 1405-1409, 1986
259. Ichikawa T, Lamb JC, Christensson PJ, Hartley-Asp B, Issacs JT: The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res 52: 3022-3028, 1992
260. Vukanovic J, Passaniti A, Hirata T, Traystman RJ, Hartley-Asp B, Isaacs JT: Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 53: 1833-1837, 1993
261. Karussis DM, Lehmann D, Slavin S, Vourka-Karussis U, Mizrachi-Koll R, Ovadia H, Kalland T, Abramsky O: Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proceedings of the National Academy of Sciences U.S.A. 90: 6400-6404, 1993
262. Borgström P, Torres Filho P, Vajkoczy P, Strandgarden K, Polaçek J, Hartley-Asp B: The quinoline-3-carboxamide Linomide inhibits angiogenesis in vivo. Cancer Chemother Pharmacol 34: 280-286, 1994
263. Vukanovic J, Isaacs JT: Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 55: 1499-1504, 1995
264. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Nat Acad Sci USA 91: 4082-4085, 1994
265. Krishnan EC, Krishnan J, Jewell B, Bhatia P, Jewell WR: Dose-dependent radiation effect of microvascular and repair. J Natl Cancer Inst 79: 1321-1325, 1987
266. Krishnan EC, Krishnan L, Jewell WR: Immediate effect of irradiation on microvasculature. Int J Radiat Oncol Biol Phys 15: 147-150, 1988
267. Prionas SD, Kowalski J, Fajardo LF, Kaplan I, Kwan HH, Allison AC: Effects of X-irradiation on angiogenesis. Radiat Res 124: 43-49, 1990
268. Tryggvason K, Höyhtyä M, Pyke C: Type-IV collagenases in invasive tumors. Breast Ca Res Trtmt 24: 209-218, 1993
269. Cottam DW, Rees RC: Regulation of matrix metalloproteinases: their role in tumor invasion and metastasis (review). Int J Oncol 2: 861-872, 1993
270. Redwood SM, Liu BC-S, Weiss RE, Hodge DE, Droller MJ: Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s). Cancer 69: 1212-1219, 1992
271. Galardy RE, Grobelny D, Foellmer HG, Fernandex LA: Inhibition of angiogenesis by the matrix metalloproteinase inhibitor N-(2R-2-(Hydroxyamidocarbonyniethyl)-4-methylpentanoyl)]-L-tryptophan methylamide. Cancer Res 54: 4715-4718, 1994
272. Davies B, Brown PD, Crimmin MJ, Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumour burden and prolongs survival of mice bearing human ovarian carcinoma xenograft. Cancer Res 53: 2087-2091, 1993
273. Chirivi RS, Garofalo A, Crimmin MJ, Bawden LJ, Brown PD, Giavazzi RG: Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58: 1-5, 1994
274. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM: Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumour growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54: 4726-4728, 1994
275. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown P, Giavazzi R: Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87: 293-298, 1995
276. Anderson IC, Shipp MA, Docherty AJP, Teicher BA: Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res (in press): 1996
277. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD: Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 55: 3629-3633, 1995
278. Sledge GW, Qulali M, Goulet R, Bone EA, Fife R: Effect of matrix metalloproteinase inhibitor on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87: 1546-1550, 1995
279. Golub LM, Lee HM, Nemiroff LA, McNamara TF, Kaplan R, Ramamurthy NS: Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J Perio Res 18: 516-526, 1983
280. Golub LM, McNamara TF, D'Angelo G, Greenwald RA, Ramamurthy NS: A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res 66: 1310-1314, 1987
281. Greenwald RA, Golub LM, Lavietes B, Ramamurthy NS, Bruber B, Laskin RS, McNamara TF: Tetracyclines inhibit human synovial collagenase in vivo and in vitro. J Rheumatol 14: 28-32, 1987
282. Zucker S, Lysik RM, Ramamurthy S, Golub LM, Wieman JM, Wilkie DP: Diversity of melanoma plasma membrane proteinase: Inhibition of collagenolytic and cytolytic activities by minocycline. J Natl Cancer Inst 75: 517-525, 1985
283. Tilley BC, Alarcón GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, Clegg DO, Leisen JCC, Buckley L, Cooper SM, Duncan H, Pillemer SR, Tuttleman M, Fowler SE: Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. Ann Int Med 122: 81-89, 1995
284. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR: Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 2: 297-321, 1991
285. Tamargo RJ, Bok RA, Brem H: Angiogenesis inhibition by minocycline. Cancer Res 51: 672-675, 1991
286. Alvarez Sotomayor E, Teicher BA, Schwartz GN, Holden SA, Menon K, Herman TS, Frei III E: Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo. Cancer Chemother Pharmacol 30: 377-384, 1992
287. Teicher BA, Alvarez Sotomayor E, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702-6704, 1992
288. Sidky YA, Borden EC: Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 47: 5155-5161, 1987
289. Brouty-Boyé D, Zetter BR: Inhibition of cell motility by interferon. Science 208: 516-518, 1980
290. Real FX, Oettgen HF, Krown SE: Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 4: 544-551, 1986
291. Rios A, Maansell PW, Newell GR, Reuben JM, Gutterman JU: Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon. J Clin Oncol 3: 506-512, 1985
292. Merigan TC: Human interferon as a therapeutic agent: a decade passes. New Eng J Med 318: 1458-1460, 1988
293. Waddell WR, Ganser GF, Cerise EJ, Loughry RW: Sulindac for polyposis of the colon. Am J Surg 41: 891-894, 1990
294. Orchard PJ, Smith III CM, Woods WG, Day DL, Dehner LP, Shapiro R: Treatment of haemangioendotheliomas with alpha interferon. Lancet 2: 565-567, 1989
295. Hoffman MA, Wadler S: Mechanisms by which Interferon potentiates chemotherapy. Cancer Invest (11)3: 310-313. 1993
296. White CW, Wolf SJ, Korones DM, Sondheimer HM, Tosi MF, Yu A: Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a. J Pediatr 118: 59-66, 1991
297. Ezekowitz RAB, Phil D, Mulliken JB, Folkman J: Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. New Eng J Med 326: 1456-1463, 1992
298. Toma S, Melioli G, Palumbo R, Rosso R: Recombinant interleukin-2 and a-2a-interferon in pre-treated advanced soft tissue sarcomas. Int J Oncol 2: 997-1001, 1993
299. Iwagaki H, Hizuta A, Yoshino T, Mannami T, Moriyasu F, Tanaka N, Orita K: Complete regression of advanced liposarcoma of the anterior chest wall with interferon-alpha and tumor necrosis factor-alpha. Anticancer Res 13: 13-16, 1993
300. Cohji K, Fidler I, Tsan R, Radinsky R, von Eschenbach A, Tsuruo T, Nakajima M: Human recombinant interferonsbeta and -gamma decrease gelatinase production and invasion by human KG-2 renal-carcinoma cells. Int J Cancer 58: 380-384, 1994
301. Teicher BA, Holden SA, Chen Y-N, Ara G, Korbut TT, Northey D: CAI: effects on cytotoxic therapies in vitro and in vivo. Cancer Chemother Pharmacol (34)6: 515-522, 1994
302. Folkman J. Ingber DE: Angiostatic steroids: method of discovery and mechanism of action. Ann Surg 206: 374-383, 1987
303. Ingber DE, Madri JA, Folkman J: A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology 119: 1768-1775, 1986
304. Grunt TW, Lametschwadtner A, Karrer K, Staindl O: The angioarchitecture of the Lewis lung carcinoma in laboratory mice. Scan Electron Microsc 11: 557-574, 1986
305. Grunt TW, Lametschwadtner K, Karrer A: The characteristic structural feature of the blood vessels of the Lewis lung carcinoma. Scan Electron Microsc 11 575-589, 1986
306. Killough JH, Magill GB, Smith RC: The treatment of amebiasis with fumagillin. Science 115: 71-72, 1952
307. Katznelson H, Jamieson CA: Control of nosema disease of honeybees with fumagillin. Science 115: 70-71, 1952
308. Setchell KDR, Borriello SP, Kirk DN, Axelson M: Non-steroidal estrogens of dietary origin: possible role in hormone-dependent disease. Am J Clin Nutr 40: 569-578, 1984
309. Messina M, Barnes S: The role of soy products in reducing risk of cancer. J Nutl Cancer Inst 83: 541-546, 1991
310. Hunter T, Cooper JA: Protein-tyrosinc kinase. Ann Rev Biochem 54: 897-930, 1985
311. Takano S, Gately S, Neville M, Herblin WF, Gross JL, Brom S: Suramin, an inhibitor of angiogenesis, suppresses enclothelial cell growth, migration and plasminogen activator activity. Proc Amer Assoc Cancer Res 34: 74, 1993
312. Danesi R, Del Blanchi S, Soldani P, Campagni A, La Rocca RV, Myers CE, Paparelli A, Del Tacca M: Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer 68: 932-938, 1993
313. Stein CA, LaRocca RV, Thomas R, McAtee N, Meyers CE: Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7: 499-508, 1989
314. Yayon A, Klagshrun M: Autocrine transformation by chiineric signal peptide-basic fibroblast growth factor: reversal by suramin. Proc Nat Acad Sci USA 87: 5346-5350, 1990
315. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Hngelhard H, Perricone M, Eidsvoog K, Brem S: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 54: 2654-2660, 1994
316. Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 13: 765-782, 1995